Summary of the technology
Project ID : 7-2011-2623
Description of the technology
Antibodies, Vaccinations, Drug delivery, Immunology, Adjuvants, Alumina
In vivo proof of concept
The lack of suitable adjuvants is considered the main obstacle in the development of new vaccines against incurable diseases.
- An entrapment methodology of proteins in alumina
- Alumina polymerization by the sol-gel process
- Antigen-specific IgG titers exceeding 1:1,000,000 obtained in several mice using a single immunization (prime only) with low amount of antigen (7.2ugr x 1 vs. 25ugr x 3 in conventional adsorbed vaccines).
- Antigen-specific IgG titers exceeding 1:256,000 obtained using extremely low antigen concentrations (2.5ugr, equivalent to 2 conventional immunizations using only 5% of the amount of antigen.
Fig. 1: Comparison of antigen-specific IgG titer following a single immunization with variuos composite alumina entrapped vaccines (A-4, C-3, D-1, D-2, D-3, D-4, D-5) to
immunization with antigen only (B-1) and to immunization with conventional alumina adsorbed vaccines (B-3, Alhydrogel, Sigma). All vaccines contained 7.2ug antigen
(Ovalbumin grade V, Sigma) and 25ug Al3+ in the form of alumina, except B-1 which contained antigen only
- The based on Alumina adjuvants, FDA approved for human use
- Enhanced immune response - both humoral and cellular (TH1 & TH2)
- Vaccine stability: thermal, pH, radiation
- Controlled release of the antigen
- Controlled release of an organic adjuvant
- Increasing the repertoire of existing vaccine adjutants; synergism
- Reduced toxicity
- Convenient administration: Oral, nasal, pulmonary and topical
- Entrapment of live or attenuated cells and cell lysate
- Combined alumina entrapped and adsorbed matrices
- Reducing the number of required immunizations to obtain a safe, potent immune response and a long-lasting immunological memory.
- The technology enables to prolong its shelf-life and to allow less restrictive storage condition. Therefore, enabling price reduction